Faced with tight product launch deadlines, Boehringer Ingelheim prioritized speed and stability for its CRM transition.

Choosing Veeva Vault CRM after the Veeva Summit, the company aims for a smooth rollout across its organizational units — balancing low training needs, scalability, and pharma-specific expertise.

Summary

• Active mainly in the Nordics & Benelux, with 20 products in pipeline
• Decision made after Veeva Summit due to good pharma knowledge and stability
• Global rollout based on standard OOTB solution unless exceptions are justified

❓ Q&A:

Q1. Would Salesforce have been a better option now?

🔴 No – at the time of decision, Salesforce had no live demo or concrete offer. Migration had to start immediately due to product launch schedules.

Q2. Rollout strategy?

🟢 Migration will occur by organization (org) rather than country. Currently, BI operates across 5 orgs.

Q3. What about data warehouse compatibility?

🟠 The data warehouse setup may not support org-by-org migration. Vault CRM’s data model is similar but not identical to Veeva CRM.

Q4. Is end-user training required?

🟢 Veeva claims minimal training is needed, though some differences may still require onboarding.

Q5. Can historical reports be migrated?

🔴 No – reports must be rebuilt manually.

Q6. Are Veeva’s promises realistic?

🟠 Veeva provides clear communication about what is and isn’t possible, but execution still needs to be validated.